News

Biotechnology

Novo Nordisk To Acquire Dicerna Pharmaceuticals for $3.3 Billion

Kimberly Redmond | Equities.com |

Danish drugmaker Novo Nordisk A/S plans to buy US-based biotech Dicerna Pharmaceuticals Inc in a $3.3 billion cash deal.

Under the terms of the agreement announced Thursday, Novo will pay $38.25 per share in cash, an 80% premium to Dicerna’s closing price on Nov. 17. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435 

Based in Lexington, Massachusetts, Dicerna’s drug development has...


Samsung Group To Invest $205 Billion Globally Over Next Three Years

Kimberly Redmond | Equities.com |

Samsung Group will invest $205 billion (240 trillion won) over the next three years to expand its global footprint in key industries like biopharmaceuticals, robotics and next-gen telecommunications.

On Tuesday, the tech giant unveiled the plan, saying it is aimed at preparing Samsung “for great changes in industry, international order, and social structure expected after the COVID-19 pandemic.”


Amgen Beats Q2 Estimates But Guides Lower for Full Year

Reuters | Equities.com |

U.S. biotech Amgen Inc on Tuesday said its second-quarter revenue rose 5%, but recovery from the COVID-19 pandemic, which has limited patient interactions with healthcare providers, is expected to hit sales for the rest of 2021.

The pandemic "has suppressed the volume of new patients starting treatment," the company said in a statement.


Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program for Up to $1.2 Billion

Reuters | Equities.com |

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

The acquisition is in line with Novo's strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth.


Sponsored Financial Content

Market Movers